Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

NCT ID: NCT01373671

Last Updated: 2020-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 764 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2014-05-31

Brief Summary

The primary objective of this protocol is to collect the 2-dimensional (2D) screening and diagnostic images, and 3-dimensional (3D) Digital Breast Tomosynthesis (DBT) scans from patient mammography examinations acquired on various commercially available Full Field Digital Mammography (FFDM) systems and the Siemens Inspiration DBT system, respectively.

Detailed Description

The image collection includes FFDM images and both raw and presentation data from the DBT system. The FFDM mammograms are performed using standard care screening or diagnostic mammography from various commercially available FFDM systems. All DBT images are acquired on the Inspiration DBT system specifically for the study, in addition to the clinically indicated screening mammograms. DBT images are read at the clinical sites and any DBT findings were investigated according to standard care.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Mammography exam

Siemens DBT scan

Group Type: OTHER

SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM

Intervention Type: DEVICE

DBT scan

Interventions

SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM

DBT scan

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

All subjects enrolled into the collection study must:

• Provide signed informed consent after receiving a verbal and written explanation of the purpose and nature of the study
• be females, 40 years of age or older at the screening mammographic evaluation or age 30 or older presenting for a biopsy and have one of the following mammograms:

o Normal cases at screening (BI-RADS® 1, 2 and 3):

• have a screening mammogram that includes the four standard screening views (RCC, RMLO, LCC and LMLO), as well as have both MLO and CC DBT scans of each breast,

o Actionable cases at screening (BI-RADS® 0, 4 or 5) with final BI-RADS® 1, 2, 3, 4 or 5:

• have a screening mammogram with four SSVs and any clinically necessary diagnostic mammographic views, such as straight lateral projections, rolled, magnification view and spot compression views, and, both MLO and CC DBT scans of each breast plus 4 SSVs repeated at the diagnostic or biopsy visit if the screening images are unavailable or were acquired more than 45 days prior to DBT acquisition,
• have supporting ground-truth documentation for the final BI-RADS® assessment as follows:

• A one (1) year FFDM follow up without evidence of cancer for normal cases not undergoing biopsy
• A six (6) or twelve (12) month FFDM follow up confirming benign status for biopsy proven benign cases
• Pathology report for either benign or malignant biopsy finding

Exclusion Criteria

Subjects with any of the following conditions or who have had the following procedures will be excluded from this study:

• Pregnant women or women who believe they may be pregnant or are trying to become pregnant.
• Mastectomy patients
• Subjects who have had lumpectomy ≤ 5 years prior to the study entry
• Inmates (in accordance with 45 CFR 46.306) or mentally disabled individuals
• BI-RADS® Category 6 (e.g., for which the mammogram was performed for the purpose of planning cancer therapy)
• BI-RADS® Category 4 or 5 without confirming pathology reports will be considered incomplete
• Subjects with mammograms that lack the required views or with views judged to be technically inadequate will be considered incomplete and the cases will not be considered for the MRMC reader studies
• Subjects being accrued from the screening population who know that they will not be in the United States or available for follow up mammograms in one year.

• Minimum Eligible Age: 30 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Siemens Medical Solutions USA - CSG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Agnes Lazar

Role:

Siemens Medical Solutions USA, Inc

Locations

Siemens Medical Solutions

Malvern, Pennsylvania, United States

Countries

United States

Other Identifiers

SMS-SP09-01

Identifier Type: -

Identifier Source: org_study_id